Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Guided Posters

Pituitary Clinical

Previous section
Pituitary Basic
Table of contents
Next section
Reproduction

ea0056gp202 | Pituitary Clinical | ECE2018

Endoscopic vs microscopic transsphenoidal surgery for Cushing’s disease: a systematic review and meta-analysis

Broersen Leonie H A , Biermasz Nienke R , van Furth Wouter R , de Vries Friso , Verstegen Marco J T , Dekkers Olaf M , Pereira Alberto M

Background: Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, resulting in glucocorticoid excess. First-choice treatment is transsphenoidal pituitary surgery, using either a microscopic or endoscopic technique. Convincing evidence supporting the choice for one of both techniques, either based on treatment results or complication rate, is lacking.Objective: We aimed to compare endoscopic and microscopic...
0 shares

ea0056gp203 | Pituitary Clinical | ECE2018

Factors predicting comorbidities in cured patients with Cushing’s syndrome

Schernthaner-Reiter Marie Helene , Siess Christina , Gessl Alois , Scheuba Christian , Wolfsberger Stefan , Riss Philipp , Knosp Engelbert , Luger Anton , Vila Greisa

Introduction: In patients with cured Cushing’s syndrome, comorbidities often persist after remission of glucocorticoid excess. Here we investigate long-term comorbidities in patients with Cushing’s syndrome in remission, and their relationship to metabolic and hormonal markers at the initial diagnosis of the disease.Methods/design: We evaluated 118 patients with cured Cushing’s syndrome (55 Cushing’s disease, 55 adrenal Cushing’s...
0 shares

ea0056gp204 | Pituitary Clinical | ECE2018

Long-term efficacy and safety of once-monthly pasireotide in patients with Cushing’s disease: A Phase III extension study

Fleseriu Maria , Petersenn Stephan , Biller Beverly M K , Kadioglu Pinar , De Block Christophe , T'Sjoen Guy , Vantyghem Marie C , Tauchmanova Libuse , Ravichandran Shoba , Roughton Michael , Lacroix Andre , Newell-Price John

Introduction: The 12-month results of a multicentre, double-blind, Phase III study showing the efficacy and safety of a monthly, long-acting formulation of pasireotide in Cushing’s disease (CD) patients have been reported previously (Lacroix et al. Lancet Diabetes Endocrinol 2018). The results of the extension phase of this study are reported here.Methods: Patients (n=150) with persistent/recurrent or de novo CD and mean u...
0 shares

ea0056gp205 | Pituitary Clinical | ECE2018

Predictors of response to long-acting pasireotide in patients with Cushing’s disease during a Phase III study

Witek Przemyslaw , Biller Beverly M K , Lacroix Andre , Feelders Richard , Li Yiming , Geer Eliza B , Brue Thierry , Ravichandran Shoba , Tauchmanova Libuse , Roughton Michael , Petersenn Stephan

Introduction: Long-acting pasireotide reduced urinary free cortisol (UFC) in most patients with Cushing’s disease (CD) during a large Phase III study (Lacroix et al. Lancet Diabetes Endocrinol 2018). The analyses presented here explored the impact of baseline characteristics on response to long-acting pasireotide.Methods: 150 patients with persistent, recurrent or de novo CD and mean UFC (mUFC; from three 24-hour samples collected ...
0 shares

ea0056gp206 | Pituitary Clinical | ECE2018

Clinicopathological correlations in pituitary thyrotroph tumors from a cohort of 23 patients

Capraru Oana-Maria , Vasiljevic Alexandre , Gaillard Celine , Borson-Chazot Francoise , Raverot Veronique , Jouanneau Emmanuel , Trouillas Jacqueline , Raverot Gerald

The thyrotroph tumors or pituitary neuroendocrine tumors (PitNET) classify as tumors of Pit-1 family. These tumors are rare and may be monohormonal, secreting only TSH, or plurihormonal, secreting TSH-GH±PRL, with or without acromegaly. The objectives of this retrospective study were to confirm the frequency of the plurihormonal subtype and to compare the clinical, biological and pathological characteristics of these two pathological subtypes. We retrospectively studied t...
0 shares

ea0056gp207 | Pituitary Clinical | ECE2018

Molecular profiling of non-functioning pituitary adenomas does not support pharmacological therapeutic options

Gil Joan , Blanco Alberto , Serra Guillermo , Salinas Isabel , Webb Susan M , Hostalot Cristina , Obiols Gabriel , Valassi Elena , Roig Olga , Sesmilo Gemma , Villabona Carles , Jorda Mireia , Puig-Domingo Manel

Non-functioning pituitary adenomas (NFPA) are the most common pituitary tumours. They usually come to medical attention because of a mass effect and/or hypopituitarism. Tumour shrinkage during therapy with either dopamine agonists (DA) or somatostatin analogues (SSA) has been previously reported in some cases; however, response of NFPA to medical treatment is still poor and unpredictable. Our aim was to explore the molecular mechanisms underlying this lack of efficacy through ...
0 shares

ea0056gp208 | Pituitary Clinical | ECE2018

The role of clomiphene citrate in the resolution of hypogonadism in male patients with prolactinomas under cabergoline therapy

Vilar Lucio , Vilar Clarice , Lyra Ruy , The Ana Carolina , Trovao Erik , Gadelha Patricia , Cardozo Izabela , Borges Thaize , Sampaio Icaro , Ferreira Liana , Albuquerque Luciano

Background: Dopamine agonists (DA) are the treatment of choice of prolactinomas. Cabergoline is preferable to bromocriptine due to its greater effectiveness and better tolerabilitiy. However, up to 30–50% of male patients may persist with low levels of testosterone despite prolactin (PRL) normalization under DA therapy or the use of the maximum tolerated dose of DA. The aim of this prospective open study was to evaluate the efficacy of the SERM clomiphene citrate (CC) in ...
1 shares

ea0056gp209 | Pituitary Clinical | ECE2018

Cabergoline - therapy for 121 giant invasive prolactinomas

Astafyeva Liudmila , Kadashev Boris , Kalinin Pavel , Kutin Maxim , Fomichev Dmitriy , Sharipov Oleg , Klochkova Irina , Sidneva Yuliya

Objective: Prospective study of cabergoline effect in newly diagnosed patients with giant invasive prolactinomas.Patients and methods: The study group included 121 patients with giant prolactinomas (tumors larger than 40 mm in size); among them 49 patients had tumors larger than 60 mm in size. 91 male and 30 female aged 16–67 years (median 37) were treated with 0.5–3.5 mg/week (mean 1.5 mg) cabergoline. The treatment period was 6–120 month...
0 shares

ea0056gp210 | Pituitary Clinical | ECE2018

Endocrine disorders in adults after allogenic hematopoietic stem cell transplant

Bogdanet Delia , Herlihy Naoimh , Reddin Catriona , Hayden Patrick , Healy Marie-Louise

Background: Over the last 20 years there have been significant advances in stem cell transplantation (SCT) in adults for haematological malignancies leading to improved survival. Endocrine disorders are among the most common complications in survivors after hematopoietic allogeneic stem cell transplant (HSCT), but data on adult transplant patients are still scarce.Methods: This is a retrospective study which included 284 adult patients (94 females and 19...
0 shares

ea0056gp211 | Pituitary Clinical | ECE2018

A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors

de Filette Jeroen , Andreescu Corina , Cools Filip , Bravenboer Bert , Velkeniers Brigitte

Background: Monoclonal antibodies targeting CTLA-4 and PD-1/PD-L1 are promising for a wide range of advanced malignacies. These immune checkpoint inhibitors (ICI) provoke endocrine adverse events including hypopituitarism and primary thyroid disease.Methods: PubMed was searched through August 22nd, 2017, for relevant articles on endocrinopathies and ICI, by two reviewers independently (J.d.F. and C.A.). The weighted incidence and odds-ratio were estimate...
0 shares

ea0056gp212 | Pituitary Clinical | ECE2018

Predictors of failure to respond to fluid restriction and furosemide efficacy prediction in patients presenting Syndrome of Inappropriate Antidiuretic while receiving parenteral nutrition. Prospective Multicenter Study

Gomez-Hoyos Emilia , Ortola-Buigues Ana , Casariego Alfonso Vidal , Delgado Yaiza Garcia , Breton Maria Julia Oncon , Gonzalez Angel Luis Abad , Perez Luis Miguel Luengo , Martin Pilar Matia , Guerrero Maria Jose Tapia , De Luis Roman Daniel

Introduction: Syndrome of Inappropriate Antidiuretic (SIAD) is the most frequent cause of hyponatremia in parenteral nutrition (PN) patients. Yet studies concerning SIAD therapy are lacking. Our objective was to describe SIAD treatment and determine pre-treatment predictors of failure to respond to fluid restriction (FR) and furosemide efficacy prediction in a group of patients with SIAD while receiving PN.Methods: Prospective, non-interventional, multic...
0 shares

ea0056gp213 | Pituitary Clinical | ECE2018

Abstract withdrawn....
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more